Kaskela Law LLC announces that it is investigating Protalix BioTherapeutics, Inc. (NYSE: PLX) (“Protalix”) on behalf of the company’s shareholders.

Since May 2023, shares of Protalix common stock have declined in value from a trading price of approximately $3.25 per share to a trading price of below $1.25 per share, a decline of over 61% in value.

The investigation seeks to determine whether Protalix and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties to the company’s investors.

Protalix shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or by copying and pasting the link into your browser):

https://kaskelalaw.com/case/protalix-biotherapeutics/

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

This notice may constitute attorney advertising in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240917066480/en/